Simplifying Global Compliance
Contraceptive Patch Should Stay, But With Stronger Labeling, REMs
Washington Drug Letter
A joint FDA advisory panel is recommending Janssen Pharmaceuticals’ Ortho Evra transdermal contraceptive patch remain on the market as its benefits outweigh the risk of blood clots for most women.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing